Drugs / (+)-Alpha-Dihydrotetrabenazine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02844179 | Jul 2016 → Jun 2017 | — | Kirk A. Frey | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (+)-Alpha-Dihydrotetrabenazine | “(+)-Alpha-Dihydrotetrabenazine Phase I” NCT02844179 ↗ |
| Known as | HTBZ | “Single dose administration of (+)-alpha-Dihydrotetrabenazine (HTBZ), escalating dosage amounts 7.5 - 30 mg orally” NCT02844179 ↗ |
| Route | Oral | “7.5 - 30 mg orally” NCT02844179 ↗ |